-
International Journal of Molecular... Jun 2024In yeast , there are two translation termination factors, eRF1 (Sup45) and eRF3 (Sup35), which are essential for viability. Previous studies have revealed that presence...
In yeast , there are two translation termination factors, eRF1 (Sup45) and eRF3 (Sup35), which are essential for viability. Previous studies have revealed that presence of nonsense mutations in these genes leads to amplification of mutant alleles ( and ), which appears to be necessary for the viability of such cells. However, the mechanism of this phenomenon remained unclear. In this study, we used RNA-Seq and proteome analysis to reveal the complete set of gene expression changes that occur during cellular adaptation to the introduction of the nonsense allele. Our analysis demonstrated significant changes in the transcription of genes that control the cell cycle: decreases in the expression of genes of the anaphase promoting complex APC/C (, ) and their activator , and increases in the expression of the transcription factor , the main cell cycle kinase , and cyclins that induce DNA biosynthesis. We propose a model according to which yeast adaptation to nonsense mutations in the translation termination factor genes occurs as a result of a delayed cell cycle progression beyond the G2-M stage, which leads to an extension of the S and G2 phases and an increase in the number of copies of the mutant allele.
Topics: Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Codon, Nonsense; Gene Expression Regulation, Fungal; Peptide Termination Factors; Adaptation, Physiological; Cell Cycle
PubMed: 38928012
DOI: 10.3390/ijms25126308 -
International Journal of Molecular... Jun 2024Oxidative stress represents a critical facet of the array of abiotic stresses affecting crop growth and yield. In this paper, we investigated the potential differences...
Oxidative stress represents a critical facet of the array of abiotic stresses affecting crop growth and yield. In this paper, we investigated the potential differences in the functions of two highly homologous Arabidopsis DSS1 proteins in terms of maintaining genome integrity and response to oxidative stress. In the context of homologous recombination (HR), it was shown that overexpressing AtDSS1(I) using a functional complementation test increases the resistance of the Δ mutant of to genotoxic agents. This indicates its conserved role in DNA repair via HR. To investigate the global transcriptome changes occurring in plant mutant lines, gene expression analysis was conducted using Illumina RNA sequencing technology. Individual RNA libraries were constructed from three total RNA samples isolated from , , and wild-type (WT) plants under hydrogen peroxide-induced stress. RNA-Seq data analysis and real-time PCR identification revealed major changes in gene expression between mutant lines and WT, while the and mutant lines exhibited analogous transcription profiles. The Kyoto Encyclopedia of Genes and Genomes enrichment analysis revealed significantly enriched metabolic pathways. Notably, genes associated with HR were upregulated in mutants compared to the WT. Otherwise, genes of the metabolic pathway responsible for the synthesis of secondary metabolites were downregulated in both mutant lines. These findings highlight the importance of understanding the molecular mechanisms of plant responses to oxidative stress.
Topics: Oxidative Stress; Arabidopsis; Seedlings; Transcriptome; Arabidopsis Proteins; Gene Expression Regulation, Plant; Gene Knockout Techniques; Gene Expression Profiling; Mutation; Hydrogen Peroxide
PubMed: 38927997
DOI: 10.3390/ijms25126291 -
Genes Jun 2024Retinitis pigmentosa (RP) is a heterogeneous inherited retinal disorder. Mutations in cause autosomal recessive (AR) RP. We aimed to characterize the genotype,...
Retinitis pigmentosa (RP) is a heterogeneous inherited retinal disorder. Mutations in cause autosomal recessive (AR) RP. We aimed to characterize the genotype, expression pattern, and phenotype in a large cohort of cases. Sanger and whole exome sequencing were used to identify the variants. Medical records were reviewed and analyzed. Thirty-one patients with biallelic mutations were identified: 28 homozygous for c.226C>T (p.R76*), 2 compound heterozygous for p.R76* and c.3G>A (p.M1?), and one homozygous for c.247C>T (p.R83*). c.226C>T is a founder mutation among patients of Jewish descent. The clinical parameters were less severe in compared to and cases. RT-PCR analysis in fibroblast cells revealed the presence of four different transcripts in both WT and mutant samples with a lower percentage of the WT transcript in patients. Sequence analysis identified an exonic sequence enhancer (ESE) that includes the c.226 position which is affected by the mutation. mutations are an uncommon cause of IRD worldwide but are not rare among Ashkenazi Jews. Our data indicate that p.R76* affect an ESE which in turn results in the pronounced skipping of exon 3. Therefore, RNA-based therapies might show low efficacy since the mutant transcripts are spliced.
Topics: Humans; Retinitis Pigmentosa; Female; Male; Mutation; Adult; Jews; Exome Sequencing; Pedigree; Eye Proteins; Phenotype; Middle Aged; Adolescent
PubMed: 38927740
DOI: 10.3390/genes15060804 -
Genes Jun 2024Many enzymes in the Raetz pathway for lipid A biosynthesis in are essential. A homologous protein Pa1792|LpxH in is known to complement the loss of LpxH in ....
Many enzymes in the Raetz pathway for lipid A biosynthesis in are essential. A homologous protein Pa1792|LpxH in is known to complement the loss of LpxH in . Genome-wide transposon-insertion sequencing analysis indicates that is essential in . However, genetic analysis of in has not been carried out, partly because the conditional alleles of essential genes are not readily constructed. In this study, we first constructed a plasmid-based temperature-sensitive mutant or in PAO1. Spot-plating assay indicated that was lethal at a restrictive temperature, confirming its essentiality for growth. Microscopic analysis revealed that exhibited an oval-shaped morphology, suggesting that was required for rod-shape formation. SDS-PAGE and Western blotting analysis showed that failed to synthesize lipid A, consistent with its function in lipid A biosynthesis. Strong expression of but not the non-homologous isoenzyme or impeded growth and caused cell lysis, implying that -specific cofactors were required for this toxic effect in . Together, our results demonstrate that is essential for lipid A biosynthesis, rod-shaped growth, and viability in . We propose that this plasmid-based conditional allele is a useful tool for the genetic study of essential genes in .
Topics: Pseudomonas aeruginosa; Plasmids; Bacterial Proteins; Temperature; Mutation; Lipid A; Escherichia coli
PubMed: 38927720
DOI: 10.3390/genes15060784 -
Genes Jun 2024is a LIM-homeodomain transcription factor that affects body size in mammals by regulating the secretion of pituitary hormones. Akita, Shiba Inu, and Mame Shiba Inu dogs...
is a LIM-homeodomain transcription factor that affects body size in mammals by regulating the secretion of pituitary hormones. Akita, Shiba Inu, and Mame Shiba Inu dogs are Japanese native dog breeds that have different body sizes. To determine whether plays a role in the differing body sizes of these three dog breeds, we sequenced the gene in the three breeds, which led to the identification of an SNP in codon 280 (S280N) associated with body size. The allele frequency at this SNP differed significantly between the large Akita and the two kinds of smaller Shiba dogs. To validate the function of this SNP on body size, we introduced this change into the gene of mice. Homozygous mutant mice (S279N) were found to have significantly increased body lengths and weights compared to heterozygous mutant (S279N) and wild-type (S279N) mice several weeks after weaning. These results demonstrate that a nonsynonymous substitution in plays an important role in regulating body size in mammals.
Topics: Animals; LIM-Homeodomain Proteins; Transcription Factors; Mice; Body Size; Dogs; Polymorphism, Single Nucleotide; Gene Frequency; Male; Female
PubMed: 38927675
DOI: 10.3390/genes15060739 -
Genes May 2024Grain filling is critical for determining yield and quality, raising the question of whether central coordinators exist to facilitate the uptake and storage of various...
Grain filling is critical for determining yield and quality, raising the question of whether central coordinators exist to facilitate the uptake and storage of various substances from maternal to filial tissues. The duplicate NAC transcription factors ZmNAC128 and ZmNAC130 could potentially serve as central coordinators. By analyzing differentially expressed genes from mutants across different genetic backgrounds and growing years, we identified 243 highly and differentially expressed genes (hdEGs) as the core target genes. These 243 hdEGs were associated with storage metabolism and transporters. ZmNAC128 and ZmNAC130 play vital roles in storage metabolism, and this study revealed two additional starch metabolism-related genes, and , as their direct targets. A key finding of this study was the inclusion of 17 transporter genes within the 243 hdEGs, with significant alterations in the levels of more than 10 elements/substances in mutant kernels. Among them, six out of the nine upregulated transporter genes were linked to the transport of heavy metals and metalloids (HMMs), which was consistent with the enrichment of cadmium, lead, and arsenic observed in mutant kernels. Interestingly, the levels of Mg and Zn, minerals important to biofortification efforts, were reduced in mutant kernels. In addition to their direct involvement in sugar transport, ZmNAC128 and ZmNAC130 also activate the expression of the endosperm-preferential nitrogen and phosphate transporters and . This coordinated regulation limits the intake of HMMs, enhances biofortification, and facilitates the uptake and storage of essential nutrients.
Topics: Zea mays; Gene Expression Regulation, Plant; Plant Proteins; Transcription Factors; Seeds; Edible Grain; Nutrients
PubMed: 38927600
DOI: 10.3390/genes15060663 -
Biomolecules May 2024The p53 protein is the master regulator of cellular integrity, primarily due to its tumor-suppressing functions. Approximately half of all human cancers carry mutations... (Review)
Review
The p53 protein is the master regulator of cellular integrity, primarily due to its tumor-suppressing functions. Approximately half of all human cancers carry mutations in the TP53 gene, which not only abrogate the tumor-suppressive functions but also confer p53 mutant proteins with oncogenic potential. The latter is achieved through so-called gain-of-function (GOF) mutations that promote cancer progression, metastasis, and therapy resistance by deregulating transcriptional networks, signaling pathways, metabolism, immune surveillance, and cellular compositions of the microenvironment. Despite recent progress in understanding the complexity of mutp53 in neoplastic development, the exact mechanisms of how mutp53 contributes to cancer development and how they escape proteasomal and lysosomal degradation remain only partially understood. In this review, we address recent findings in the field of oncogenic functions of mutp53 specifically regarding, but not limited to, its implications in metabolic pathways, the secretome of cancer cells, the cancer microenvironment, and the regulating scenarios of the aberrant proteasomal degradation. By analyzing proteasomal and lysosomal protein degradation, as well as its connection with autophagy, we propose new therapeutical approaches that aim to destabilize mutp53 proteins and deactivate its oncogenic functions, thereby providing a fundamental basis for further investigation and rational treatment approaches for TP53-mutated cancers.
Topics: Humans; Tumor Suppressor Protein p53; Neoplasms; Tumor Microenvironment; Proteolysis; Proteasome Endopeptidase Complex; Autophagy; Animals; Mutation; Lysosomes; Carcinogenesis
PubMed: 38927053
DOI: 10.3390/biom14060649 -
Biomolecules May 2024Chronic myeloid leukemia (CML) is an oncological myeloproliferative disorder that accounts for 15 to 20% of all adult leukemia cases. The molecular basis of this disease... (Review)
Review
Chronic myeloid leukemia (CML) is an oncological myeloproliferative disorder that accounts for 15 to 20% of all adult leukemia cases. The molecular basis of this disease lies in the formation of a chimeric oncogene BCR-ABL1. The protein product of this gene, p210 BCR-ABL1, exhibits abnormally high constitutive tyrosine kinase activity. Over recent decades, several targeted tyrosine kinase inhibitors (TKIs) directed against BCR-ABL1 have been developed and introduced into clinical practice. These inhibitors suppress BCR-ABL1 activity through various mechanisms. Furthermore, the advent of RNA interference technology has enabled the highly specific inhibition of BCR-ABL1 transcript expression using small interfering RNA (siRNA). This experimental evidence opens avenues for the development of a novel therapeutic strategy for CML, termed siRNA therapy. The review delves into molecular genetic mechanisms underlying the pathogenesis of CML, challenges in CML therapy, potential molecular targets for drug development, and the latest results from the application of siRNAs in in vitro and in vivo CML models.
Topics: Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Humans; RNA, Small Interfering; Fusion Proteins, bcr-abl; Molecular Targeted Therapy; Animals; Protein Kinase Inhibitors; RNA Interference
PubMed: 38927048
DOI: 10.3390/biom14060644 -
Stem Cell Research & Therapy Jun 2024Human induced pluripotent stem cells (hiPSCs) and their differentiated cell types have a great potential for tissue repair and regeneration. While the primary focus of...
BACKGROUND
Human induced pluripotent stem cells (hiPSCs) and their differentiated cell types have a great potential for tissue repair and regeneration. While the primary focus of using hiPSCs has historically been to regenerate damaged tissue, emerging studies have shown a more potent effect of hiPSC-derived paracrine factors on tissue regeneration. However, the precise contents of the transplanted hiPSC-derived cell secretome are ambiguous. This is mainly due to the lack of tools to distinguish cell-specific secretome from host-derived proteins in a complex tissue microenvironment in vivo.
METHODS
In this study, we present the generation and characterization of a novel hiPSC line, L274G-hiPSC, expressing the murine mutant methionyl-tRNA synthetase, L274GMmMetRS, which can be used for tracking the cell specific proteome via biorthogonal non-canonical amino acid tagging (BONCAT). We assessed the trilineage differentiation potential of the L274G-hiPSCs in vitro and in vivo. Furthermore, we assessed the cell-specific proteome labelling in the L274G-hiPSC derived cardiomyocytes (L274G-hiPSC-CMs) in vitro following co-culture with wild type human umbilical vein derived endothelial cells and in vivo post transplantation in murine hearts.
RESULTS
We demonstrated that the L274G-hiPSCs exhibit typical hiPSC characteristics and that we can efficiently track the cell-specific proteome in their differentiated progenies belonging to the three germ lineages, including L274G-hiPSC-CMs. Finally, we demonstrated cell-specific BONCAT in transplanted L274G-hiPSC-CMs.
CONCLUSION
The novel L274G-hiPSC line can be used to study the cell-specific proteome of hiPSCs in vitro and in vivo, to delineate mechanisms underlying hiPSC-based cell therapies for a variety of regenerative medicine applications.
Topics: Induced Pluripotent Stem Cells; Humans; Proteome; Animals; Mice; Cell Differentiation; Myocytes, Cardiac; Amino Acids; Human Umbilical Vein Endothelial Cells; Methionine-tRNA Ligase
PubMed: 38926849
DOI: 10.1186/s13287-024-03792-3 -
Molecular Cancer Jun 2024TFE3-rearranged renal cell carcinoma (TFE3-rRCC) is a rare but highly heterogeneous renal cell carcinoma (RCC) entity, of which the clinical treatment landscape is...
BACKGROUND
TFE3-rearranged renal cell carcinoma (TFE3-rRCC) is a rare but highly heterogeneous renal cell carcinoma (RCC) entity, of which the clinical treatment landscape is largely undefined. This study aims to evaluate and compare the efficacy of different systemic treatments and further explore the molecular correlates.
METHODS
Thirty-eight patients with metastatic TFE3-rRCC were enrolled. Main outcomes included progression-free survival (PFS), overall survival, objective response rate (ORR) and disease control rate. RNA sequencing was performed on 32 tumors.
RESULTS
Patients receiving first-line immune checkpoint inhibitor (ICI) based combination therapy achieved longer PFS than those treated without ICI (median PFS: 11.5 vs. 5.1 months, P = 0.098). After stratification of fusion partners, the superior efficacy of first-line ICI based combination therapy was predominantly observed in ASPSCR1-TFE3 rRCC (median PFS: not reached vs. 6.5 months, P = 0.01; ORR: 67.5% vs. 10.0%, P = 0.019), but almost not in non-ASPSCR1-TFE3 rRCC. Transcriptomic data revealed enrichment of ECM and collagen-related signaling in ASPSCR1-TFE3 rRCC, which might interfere with the potential efficacy of anti-angiogenic monotherapy. Whereas angiogenesis and immune activities were exclusively enriched in ASPSCR1-TFE3 rRCC and promised the better clinical outcomes with ICI plus tyrosine kinase inhibitor combination therapy.
CONCLUSIONS
The current study represents the largest cohort comparing treatment outcomes and investigating molecular correlates of metastatic TFE3-rRCC based on fusion partner stratification. ICI based combination therapy could serve as an effective first-line treatment option for metastatic ASPSCR1-TFE3 rRCC patients. Regarding with other fusion subtypes, further investigations should be performed to explore the molecular mechanisms to propose pointed therapeutic strategy accordingly.
Topics: Humans; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Renal Cell; Female; Male; Middle Aged; Kidney Neoplasms; Aged; Immune Checkpoint Inhibitors; Oncogene Proteins, Fusion; Adult; Antineoplastic Combined Chemotherapy Protocols; Gene Rearrangement; Biomarkers, Tumor; Treatment Outcome; Prognosis; Intracellular Signaling Peptides and Proteins
PubMed: 38926757
DOI: 10.1186/s12943-024-02044-5